ACRV

#3980
Acrivon Therapeutics, Inc. - Common Stock
2.0 7 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
2.07
2.07
Jahresspanne
1.27
3.55
Tagesänderung
-0.96%
Monatliche Änderung
+36.18%
6 month change
+39.86%
Jahresänderung
+55.64%
Vorheriger Schlusskurs
2.0 9
Open
2.0 7
Tief
2.0 7
Hoch
2.0 7
Volumen
14
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Acrivon Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Acrivon Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Acrivon Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Acrivon Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Acrivon Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Acrivon Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Acrivon Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Acrivon Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Acrivon Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Acrivon Therapeutics, Inc. current report, Q1 FY2026
8-K

Acrivon Therapeutics, Inc. current report, Q2 FY2025

Full document

Business Context and Reporting Period

This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Acrivon Therapeutics, Inc. on June 13, 2025. The filing details the results of shareholder votes on director elections and the ratification of the independent auditor.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.

Material Changes and Voting Results

A quorum of 29,659,010 shares (94.59% of outstanding shares) was present or represented by proxy. Two proposals were acted upon:

  • Proposal One: Election of Class III Directors
    • Peter Blume-Jensen, M.D., Ph.D.: Elected with 26,612,623 votes For, 102,322 Withheld, and 2,944,065 Broker Non-Votes.
    • Derek DiRocco, Ph.D.: Elected with 24,606,548 votes For, 2,108,397 Withheld, and 2,944,065 Broker Non-Votes.
    • Santhosh Palani, Ph.D., C.F.A.: Elected with 26,246,868 votes For, 468,077 Withheld, and 2,944,065 Broker Non-Votes.
  • Proposal Two: Ratification of Auditor
    • Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
    • Votes: 29,653,924 For, 3,673 Against, 1,413 Abstain, 0 Broker Non-Votes.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of voting outcomes.

Key Facts for Investor Verification

  • Three new Class III directors were elected to serve until the 2028 Annual Meeting.
  • PricewaterhouseCoopers LLP was ratified as the independent auditor for the 2025 fiscal year.
  • Shareholder participation was high, with 94.59% of outstanding shares represented at the meeting.
  • Significant broker non-votes (2,944,065) were recorded for the director elections, indicating shares held by brokers where no voting instruction was received.

Nachrichten